Bangalore: Ankur Drugs and Pharma ended the trading as one of the top losers with a loss of 22.25 (10.10 percent). The company opened its account today on the day's highest value, but could not kept the momentum throughout the day, and at the time of closing, the price of one share was 197.95. In all 18.62 million shares were traded throughout the day with a current P/E at 10.33. The 52 week stock price chart is on the left. Ankur Drugs and Pharma is an India-based company engaged in the pharmaceutical formulations in the form of tablets, capsules, liquid orals and dry syrups; both manufactured and outsourced. It is into 100 percent contract manufacturing activity. The company's client includes Ranbaxy Laboratories, Cipla, Khandelwal Laboratories, Makers Laboratories, Hetero Healthcare, Elder Pharma, Lyka Labs, Blue cross Laboratories, Cadila Laboratories, Wockhardt, Glenmark Pharma and Parentral Drugs (India). On December 14, 2007, Vaibhav Healthcare was merged with the company. In the quarter ended June 30, 2009, the net sales of the company was 27645.15 lakh against 23114.41 lakh for the quarter ended on June 30, 2008. The net profit was at 2474.49 lakh against 2157.94 lakh. Other drugs companies have ended the day on mixed node with Wockhardt and Glenmark Pharmaceuticals going down by 3.53 and 1.59 percent and Cadila Healthcare and Ranbaxy Laboratories going up by 0.71 and 0.95 percent. With 199,980 of shares, Reliance Pharma Fund holds the highest number of shares in Ankur Drugs.